文献速递肺结节与肺癌

转移性非小细胞肺癌全身治疗的疗效-效果差距系统评估

Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer.
PubMed 文献 · Eur Respir J · 2018-12-20

该研究纳入2008至2014年荷兰七家大型教学医院收治的2989例IV期非小细胞肺癌患者,其中1214例(41%)接受一线治疗。研究计算疗效-效果因子(个体总生存除以相应治疗临床试验汇总中位总生存),发现所有方案真实世界总生存均短于临床试验,总体疗效-效果因子为0.77(95%CI 0.70-0.85;p<0.001)。真实世界患者完成治疗计划及进入后续治疗线数的比例更低,这些因素与ECOG体能状态共同解释35%的疗效-效果因子变异。

要点

  • 真实世界转移性NSCLC患者总生存较临床试验短约四分之一,疗效-效果因子0.77(95%CI 0.70-0.85;p<0.001)。
  • 患者体能状态、提前终止治疗及后续治疗线数减少部分解释疗效-效果差距。
  • 真实世界患者完成治疗计划及进入后续治疗的比例低于临床试验。

核心结论

  • 真实世界接受化疗或靶向治疗的转移性NSCLC患者总生存较临床试验纳入患者短近四分之一。
  • 患者体能状态、提前终止治疗及后续治疗线数减少部分解释了该差异。

研究设计与样本

  • 研究纳入2008至2014年荷兰七家大型教学医院网络(Santeon)收治的2989例IV期NSCLC患者。
  • 其中1214例(41%)开始一线治疗。
  • 为每例患者计算疗效-效果因子:个体总生存除以相应治疗临床试验汇总中位总生存。

主要发现

  • 所有研究方案的真实世界总生存均短于临床试验报告的总生存。
  • 总体疗效-效果因子为0.77(95%CI 0.70-0.85;p<0.001)。
  • 真实世界患者完成治疗计划的比例更低,进入后续治疗线数的比例也更低。
  • 上述参数与ECOG体能状态共同解释35%的疗效-效果因子变异。

临床怎么用

  • 评估转移性NSCLC全身治疗预后时,需考虑真实世界疗效可能低于临床试验报告。
  • 关注患者体能状态、治疗完成情况及后续治疗衔接,可能有助于缩小疗效-效果差距。

局限性

  • 研究仅基于荷兰七家教学医院网络数据,外推性需谨慎。
  • 疗效-效果因子计算依赖临床试验汇总中位总生存,可能受试验选择偏倚影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The divergence between clinical trial results and real-world outcomes is largely unknown for many cancer types. The present study aims overall to assess the efficacy-effectiveness gap (difference between outcomes in clinical trials and the real world) in systemic treatment for metastatic nonsmall cell lung cancer (NSCLC).All patients diagnosed with stage IV NSCLC between 2008 and 2014 within a network of seven Dutch large teaching hospitals (Santeon) were studied. For every patient, an efficacy-effectiveness (EE) factor was calculated by dividing individual patients' overall survival (OS) by the pooled median OS assessed from clinical trials with the respective treatment.From 2989 diagnosed patients, 1214 (41%) started with first-line treatment. For all studied regimens, real-world OS was shorter than OS reported in clinical trials. Overall, the EE factor was 0.77 (95% CI 0.70-0.85; p<0.001). Real-world patients completed their treatment plan less often and proceeded less frequently to further lines of treatment. These parameters together with Eastern Cooperative Oncology Group performance status explained 35% of the variation in EE factor.Survival of patients with metastatic NSCLC treated with chemotherapy or targeted therapy in real-world practice is nearly one-quarter shorter than for patients included in trials. Patients' performance status, earlier discontinuation and fewer subsequent lines of treatment partly explained this difference.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Cramer-van der Welle CM, Peters BJM, Schramel FMNH, et al. Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer. Eur Respir J. 2018. PMID: 30487206. doi:10.1183/13993003.01100-2018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。